Australian News.
25th June 2012
11 new drugs added to the pharmaceutical benefits scheme (PBS).
CYSTIC fibrosis sufferers will be among 45,000 people to benefit from cheaper medicines following the Federal Government's approval of 11 new medicines on the Pharmaceutical Benefits Scheme.
The new listings were announced yesterday by health minister Tanya Plibersek, who said they would provide patients with access to new, affordable treatments for a range of ailments.
Among the listed medicines is Mannitol, sold as Bronchitol, an innovative treatment developed by an Australian pharmaceutical company in an easy-to-use, portable inhaler.
Ms Plibersek said the new medicine reduced the amount of mucus build-up in the lungs of patients with cystic fibrosis.
She said it could be used by all patients over the age of six who could not use, or were not responsive to, medicines already listed on the PBS.
"In addition to Mannitol, other Australians will also benefit in the coming months from the Australian Government's decision to provide subsidised access to a further 10 medicines through the PBS," she said.
"This will ensure more patients have greater access to the medicines and treatment they need at subsidised prices."
The new medicines to be added to the PBS include aflibercept (sold as Eylea), which is for the treatment of age-related macular degeneration in patients new to drug treatment.
Ms Plibersek said the decision to list aflibercept (Eylea) would reduce the number of visits to the doctor that some macular degeneration patients needed to make to receive the injections, from every month to every two months.
Listings are subject to final arrangements being met by the suppliers of the medicines.
The decision to list aflibercept (Eylea) will benefit patients who have not previously received treatment for age-related macular degeneration, she added. “This listing of aflibercept (Eylea) will reduce the number of visits to the doctor that some patients need to make to receive the injections, from every month to every two months,” Ms Plibersek said. “Patients would have to pay more than $13,000 per year for this medicine without subsidised access through the PBS,”The maximum amount they will now pay for their prescriptions is A$5.80. she noted.
The listings, which are subject to final arrangements being met by the suppliers of the medicines, are:
• aflibercept (Eylea), for age-related macular degeneration, manufactured by Bayer;
• auranofin (Ridaura), for rheumatoid arthritis, from BNM Group;
• bortezomib (Velcade), bone marrow cancer, Janssen, a Johnson & Johnson unit;
• cabazitaxel (Jevtana), metastatic prostate cancer, Sanofi;
• denosumab (Prolia), osteoporosis, Amgen;
• etanercept (Enbrel), severe chronic psoriasis for children, Pfizer;
• human menopausal gonadotrophin (Menopur), IVF, Ferring;
• icatibant (Firazyr), hereditary angioedema (swelling that can impede breathing); Shire
• mannitol (Bronchitol), cystic fibrosis, Pharmaxis;
• pazopanib (Votrient), kidney cancer, GlaxoSmithKline; and
• rasagiline (Azilect), Parkinson’s disease, Lundbeck.
Also agrees six price hikes
The government has also agreed to increase the price of six medicines currently listed on the PBS. This will ensure a number of essential medicines continue to be available. They include: heparin injection (preservative-free) for the prevention and treatment of blood clots, idarubicin capsules (Zavedos) for the treatment of leukemia, levonorgestrel intrauterine (Mirena) for use as a contraception and treatment of abnormally heavy and pronged menstrual bleeding, metformin with glibenclamide (Glucovance) for the treatment of diabetes, methyldopa (Hydopa) for the treatment of high blood pressure and estradiol vaginal tablets (Vagifem) for use as hormone replacement therapy for postmenopausal women.
The price increases for these medicines will have no impact on concessional patients which constitute around 80% of PBS prescriptions. The maximum amount they will pay for their prescriptions is A$5.80. General patients will continue to have access to subsidized medicines and will pay between A$0.57 and A$3.54 more for these medicines.












